Ab0868 How Do Early Disease Activity and Early Clinical Response Associate With Long-Term Outcomes With Ixekizumab in Radiographic Axial Spondyloarthritis?

Background: The ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) advise that a patient be assessed for biological disease-modifying anti-rheumatic drug (bDMARD) treatment response after at least 12 weeks of treatment 1. The recommended treatment target for axSpA is inactive disease (ID) or low disease activity (LDA) 2, as together defined by an Ankylosing Spondylitis Disease Activity Score (ASDAS) 3. Objectives: This analysis aimed to explore the association between treatment response at Week (W)12 and W24, and attainment of the ASDAS Methods: This post hoc analysis included patients randomly assigned to IXE 80mg every 4 weeks (N=81) from COAST-V (NCT02696785), a Phase 3 trial that investigated the efficacy of IXE in bDMARD-naïve patients with r-axSpA. The proportion of patients who achieved the ASDAS Results: Of the 81 patients, 34 (42%) were in ID or LDA at W12 (8 ID, 26 LDA) and most of these patients met the ASDAS Conclusion: These data regarding IXE-treated patients with r-axSpA reinforce the current ASAS-EULAR and T2T recommendations, in that those who achieved ASDAS CII or ASDAS REFERENCES: 1 Ramiro SE et al. Ann Rheum Dis. 2023; 82(1):19-34 2 Smolen JS et al. Ann Rheum Dis. 2018; 77(1): 3-17 3 Machado PM et al. Ann Rheum Dis. 2018; 77(10): 1539-1540 Acknowledgements: NIL. Disclosure of Interests: Previously presented at the American College of Rheumatology - ACR Convergence 2023. Sofia Ramiro AbbVie, Eli Lilly and Company, Galapagos NV, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi, and UCB Pharma, AbbVie, Eli Lilly and Company, Galapagos NV, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi, and UCB Pharma, AbbVie, Eli Lilly and Company, Galapagos NV, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi, and UCB Pharma, Cédric Lukas AbbVie, Amgen, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly and Company, Galapagos NV, Merck Sharp & Dohme, Novartis, Pfizer, and Roche, AbbVie, Amgen, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly and Company, Galapagos NV, Merck Sharp & Dohme, Novartis, Pfizer, and Roche, AbbVie, Amgen, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly and Company, Galapagos NV, Merck Sharp & Dohme, Novartis, Pfizer, and Roche, Louis Bessette Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Sanofi, Eli Lilly and Company, Gilead, JAMP Pharma, Fresenius Kabi, Teva, Organon, and Sandoz, Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Sanofi, Eli Lilly and Company, Gilead, JAMP Pharma, Fresenius Kabi, Teva, Organon, and Sandoz, Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Sanofi, Eli Lilly and Company, Gilead, JAMP Pharma, Fresenius Kabi, Teva, Organon, and Sandoz, Pendleton Wickersham Abbvie, Amgen, Novartis, Lilly, Sanofi-Genzyme, SetPoint, Sun Pharma, Viela Bio, RegenLab, Paradigm, and AstraZeneca, Abbvie, Amgen, Novartis, Lilly, Sanofi-Genzyme, SetPoint, Sun Pharma, Viela Bio, RegenLab, Paradigm, and AstraZeneca, Soyi Liu Leage Former employee of Eli Lilly and Company, Tommaso Panni Eli Lilly and Company, Eli Lilly and Company, Rebecca Bolce Eli Lilly and Company, Eli Lilly and Company, Boris Janos Eli Lilly and Company, Eli Lilly and Company, Michael J. Nissen AbbVie, Amgen, Celgene, Eli Lilly and Company, Janssen, Novartis, and Pfizer, AbbVie, Amgen, Celgene, Eli Lilly and Company, Janssen, Novartis, and Pfizer, AbbVie, Amgen, Celgene, Eli Lilly and Company, Janssen, Novartis, and Pfizer, James Cheng-Chung Wei AbbVie, Bristol Myers Squibb, Celgene, Chugai Pharmaceutical, Eisai, Eli Lilly and Company, Janssen, Novartis, Pfizer, Sanofi-Aventis, TSH Biopharm, and UCB Pharma, AbbVie, Bristol Myers Squibb, Celgene, Chugai Pharmaceutical, Eisai, Eli Lilly and Company, Janssen, Novartis, Pfizer, Sanofi-Aventis, TSH Biopharm, and UCB Pharma, AbbVie, Bristol Myers Squibb, Celgene, Chugai Pharmaceutical, Eisai, Eli Lilly and Company, Janssen, Novartis, Pfizer, Sanofi-Aventis, TSH Biopharm, and UCB Pharma.